

7th March, 2019

To,
National Stock Exchange of India Limited
Exchange Plaza
C-1, Block 'G'Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.
Scrip Code: MARKSANS

To, BSE LimitedPhiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: **524404**

Sub.: US FDA Audit update

Dear Sirs,

This is to inform that the U.S. FDA has concluded inspection of Company's Goa facility. The inspection of the facility took place between 25th February to 6th March 2019, resulting in a Form 483 with eight observations. None of these observations are considered either critical or repetitive in nature. Company is highly confident of closing these expeditiously and remains committed to global standards of quality & compliance. The site will continue to supply to the US markets all approved ANDA's. This inspection will help Company to received pending ANDA's approval alredy filed by it.

This is for your information and records.

Thanking you.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi

Company Secretary & Manager - Legal

About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The Company's manufacturing facilities are approved by several leading regulatory agencies including UK MHRA, US FDA & Australia TGA. The Company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies. The Company is marketing these products globally.

CIN: L24110MH1992PLC066364

www.marksanspharma.com